three new ORAL drugs for multiple sclerosis...Ampyra, cladribine, and fingolimod
March 2010
Please see updated information from the FDA concerning Ampyra and the risk of seizures
These will be the first oral drugs approved for treating MS.
Ampyra (Am-PEER-ah, dalfampridine) will be available soon through specialty pharmacies...and costs over $13,000 a year.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote